Lv7
3518 积分 2021-03-24 加入
Immunodeficiencies associated with bronchiectasis
7天前
已完结
Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease
8天前
已完结
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases
8天前
已完结
An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC)
8天前
已完结
An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC)
8天前
已完结
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers
8天前
已完结
Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease
8天前
已完结
Th17 plasticity and its relevance to inflammatory bowel disease
21天前
已完结
Endotypes in bronchiectasis: moving towards precision medicine. A narrative review
24天前
已完结
Sputum proteomics identifies distinct endotypes of exacerbations in bronchiectasis
24天前
已关闭
皖公网安备34019202002308
